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Sir,
The preliminary data presented by Boegl and Prinz reflect
CD133 mRNA by RT–PCR rather than protein profiling measure-
ments by IHC as in Smith et al (2008). In our study, we used two
independent, commercially available antibodies (AC133 and
ab5558) to assess the expression of CD133 in formalin-fixed
paraffin-embedded samples of various solid tumours, including
gastric cancer. The concordance of the data between these
antibodies together with numerous positive and negative controls
described in Smith et al (2008) support the notion that the staining
detected in gastric cancer and other samples reflected the presence
of the CD133 protein as reported.
In contrast, Boegl and Prinz reported that they were not
successful in establishing specific antibody binding for CD133.
Unfortunately, no details were provided as to which antibodies
were evaluated, nor the methodology used, including controls. We
are therefore not able to provide any concrete insights into the
discrepancy with our own work. It is interesting that although
Boegl and Prinz suggest that the level of expression is reduced in
gastric cancer, there appears to be a significant number of outliers
that may suggest significant expression in a subpopulation of
tumours. From the data in Smith et al, the highest IHC staining is
in a similar percentage of tumours to the outliers from the Boegl
and Prinz experiment.
Lack of agreement between protein-based and mRNA-
based profiling measurements is commonplace in the literature
(Chen et al, 2002; Smith et al, 2002; Souchelnytskyi 2002).
It appears that CD133 may fall into this category. The RT–
PCR approach will potentially miss splice variants and will
also not measure changes in protein stability leading to increased
levels of protein. In both of these cases, changes in expression
can be detected by a protein-based method, such as IHC.
In addition, due to heterogeneity of CD133 expression in
tumours, RT–PCR can underestimate CD133 expression if no
tumour microdissection was applied. Discordance of protein and
mRNA is important to note but ultimately protein expression is
required for function and determines its potential as a therapeutic
target.
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